ATIM-07. EFFICACY AND SAFETY OF NIVOLUMAB IN PATIENTS WITH FIRST RECURRENCE OF GLIOBLASTOMA: A MULTICENTER, OPEN-LABEL, NON-COMPARATIVE STUDY (ONO-4538-19)

BACKGROUND: The anti-programmed cell death protein 1 (PD-1) immune checkpoint antibody, nivolumab, may be beneficial in patients with recurrent glioblastoma. OBJECTIVE: This open-label, non-comparative study assessed the efficacy and safety of nivolumab in Japanese patients with first recurrence of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Kagawa, Naoki, Aoki, Tomokazu, Sugiyama, Kazuhiko, Wakabayashi, Toshihiko, Arakawa, Yoshiki, Yamaguchi, Shigeru, Tanaka, Shota, Nishikawa, Ryo
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Adult Clinical Trials–Immunologic
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847716/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.007
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados